NYSE$EHAB

Enhabit Inc · Q4 2024 earnings

Q4 2024 earnings · · Investor relations

Briefing

Enhabit reported its fourth quarter 2023 results, showing a slight decrease in total net service revenue but strong growth in home health Medicare Advantage admissions and improved hospice metrics.

Enhabit, Inc. reported positive fourth quarter results driven by strong growth in home health Medicare Advantage admissions, continued payor innovation success, and improved quality outcomes. Despite a slight decrease in total net service revenue, the company saw significant increases in non-episodic admissions and improved hospice cost efficiency.

  • Net service revenue for Q4 2023 was $260.6 million, a slight decrease from $263.2 million in Q4 2022.
  • Adjusted EBITDA for Q4 2023 was $25.2 million, down from $30.3 million in Q4 2022.
  • Home health non-episodic admissions grew by 34.2% year over year, contributing to a total admission growth of 3.9%.
  • Hospice cost per day decreased to $76, stabilizing after three quarters at $77.

Headline financials

Total Revenue

$261M

No prior period
EPS (adj)

$0.06

No prior period
Adjusted EBITDA

$25.2M

No prior period
Adjusted EBITDA Margin

9.7%

No prior period
Home Health Admissions

52.0K

No prior period
Home Health Cost per Visit

$92.00

No prior period
Hospice Admissions

2.9K

No prior period
Hospice Patient Days

315.9K

No prior period
Hospice Average Daily Census

3.4K

No prior period
Hospice Revenue per Patient Day

$162.00

No prior period
Hospice Cost per Patient Day

$76.00

No prior period
Completed Episodes

54.1K

No prior period
Revenue per Episode

$2.92K

No prior period
Visits per Episode

14.3

No prior period
Total Home Health Visits

1.2M

No prior period
Capital Expenditures

-$600K

No prior period
Free Cash Flow

$11.2M

No prior period
Net Income

-$6.4M

No prior period
Operating Income

$4.9M

No prior period
Gross Profit

$127M

No prior period
Cash & Equivalents

$27.4M

No prior period
Total Assets

$1.43B

No prior period

Revenue & EPS history

Enhabit · Revenue · Quarterly

$261M

Q4 2024
Beat estimate in 3 of 4 quarters(75%)
ActualEstimate

Revenue by segment

Enhabit · $261M total across 2 segments · Q4 2024

  • Home Health
    $210M
  • Hospice
    $51.1M

Forward guidance

Enhabit is providing full-year 2024 guidance with projected net service revenue between $1,076 million and $1,102 million, Adjusted EBITDA between $98 million and $110 million, and Adjusted EPS between $0.12 and $0.43.

Tailwinds

  • Projected full-year 2024 net service revenue of $1,076 million to $1,102 million.
  • Anticipated full-year 2024 Adjusted EBITDA of $98 million to $110 million.
  • Expected full-year 2024 Adjusted EPS of $0.12 to $0.43.
  • Continued focus on payor innovation and national contracts.
  • Strong performance in quality outcomes.

Headwinds

  • The guidance ranges indicate potential variability in financial performance.
  • Continued shift to more non-episodic admissions in home health may impact consolidated revenue.
  • Uncertainties related to future impact of items outside the Company's control.
  • Potential for ongoing litigation and restructuring activities.
  • Market and economic conditions could affect demand for services.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 14 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+1.9%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+8.6%

Avg return

30 days after

40%

6 / 15 earnings

Positive

+18.2%

Q1 2025

Best reaction

-6.1%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%+0.1%
Q4 2025+0.0%+0.0%+2.9%
Q3 2025-6.1%-2.7%+13.6%
Q2 2025+15.2%+11.4%+15.1%
Q1 2025+18.2%+27.7%+31.7%
Q4 2024+1.6%+2.3%+13.3%
Q3 2024-0.4%-5.7%-12.0%
Q2 2024+0.0%-3.1%+14.8%
Q1 2024+0.0%-5.4%-13.4%
Q4 2022+0.0%-5.7%-0.4%
Q3 2023+6.1%+6.7%+19.3%
Q2 2023-2.6%-2.9%+5.6%
Q1 2023-4.5%-6.0%-2.0%
Q3 2022-0.1%+1.9%+11.3%
Q2 2022+1.7%+5.1%+20.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro